Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

GTH - Genetron Holdings Ltd - ADR


Close
4.025
0.005   0.124%

Share volume: 412,603
Last Updated: Thu 28 Mar 2024 09:00:00 PM CET
Medical Laboratories : -2.05%

PREVIOUS CLOSE
CHG
CHG%

$4.02
0.01
0.12%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
29%
Profitability 25%
Dept financing 26%
Liquidity 68%
Performance 25%
Company vs Stock growth
vs
Performance
5 Days
-3.06%
1 Month
-3.30%
3 Months
-4.57%
6 Months
-18.91%
1 Year
-5.17%
2 Year
-93.72%
Key data
Stock price
$4.02
P/E Ratio 
0.00
DAY RANGE
$4.02 - $4.02
EPS 
$0.00
52 WEEK RANGE
$0.73 - $1.31
52 WEEK CHANGE
-$0.11
MARKET CAP 
82.403 M
YIELD 
N/A
SHARES OUTSTANDING 
91.549 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.34
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$38,990
AVERAGE 30 VOLUME 
$59,104
Company detail
CEO:
Region: US
Website: genetronhealth.com
Employees: 8
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Medical Laboratories
Sector: Health Care and Social Assistance

genetron holdings limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. the company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as hccscreen, a proprietary assay for the early screening of liver cancer. it also provides in-vitro diagnostics products, including 8-gene lung cancer assay, an ivd assay product based on semiconductor sequencing to detect lung cancer; genetron 3d biochip reading instrument; idh1/tert gene assays for glioma; genetron s5, a semiconductor sequencer used in the field of gene detection; and genetron s2000 that enables gene panel sequencing. in addition, the company develops ctdna lung cancer assay for mutations in the epidermal growth factor receptor gene. it also offers development services in the areas of genomics research and clinical development in collabor

Recent news